Bio Roundup: SeaGen Scores, Dyne’s Debut, Microbiome Moves & More
Xconomy
SEPTEMBER 18, 2020
Gilead Sciences CEO Daniel O’Day has spoken openly about acquisitions as a way to build up the company’s drug pipeline. This drug class has seen a lift in recent years. This week, it made its biggest buy yet. Some of those analysts think Gilead might have overpaid but the company says there were competing offers. The FDA has approved.
67 
Let's personalize your content